Nasonex (Mometasone Furoate)

Mometasone furoate, the active ingredient in Nasonex, is a glucocorticoid presented as a nasal spray for nasal use. It treats allergic rhinitis and nasal polyps in adults and children. GNH USA supplies Nasonex as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nasonex is a nasal corticosteroid that reduces inflammation in the upper airway. - Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea. - Nasal polyps: decreases polyp size and improves nasal airflow. - Seasonal allergic rhinitis: controls symptoms triggered by pollen or other seasonal allergens.

Nasonex may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning sensation - Headache - Epistaxis (nosebleed) - Throat irritation or dryness - Cough - Altered taste or smell

Serious or Rare Side Effects: - Fungal infection of the nasal mucosa - Severe or persistent nosebleeds - Vision changes such as cataracts or glaucoma - Adrenal suppression with systemic effects - Anaphylactic or severe allergic reaction

Before prescribing Nasonex, clinicians should evaluate patient history and potential risks. - Hypersensitivity: avoid use in patients with known allergy to mometasone or any formulation component. - Nasal infection: assess and treat any active infection prior to initiating therapy. - Pediatric use: exercise caution in children under two years of age. - Systemic effects: monitor for signs of adrenal suppression with prolonged high‑dose use. - Concomitant nasal products: limit use of other topical nasal sprays to reduce irritation. - Store at room temperature: keep in the original container, protect from moisture and direct heat.

Mometasone furoate can interact with other medications that affect corticosteroid metabolism or immune function.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise local exposure. - Live vaccines: potential for reduced vaccine efficacy due to immunosuppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, ritonavir): may modestly increase exposure. - Other intranasal agents (decongestants, antihistamines): may increase local irritation or alter absorption.